EXenatide Study of Cardiovascular Event Lowering
The EXenatide Study of Cardiovascular Event Lowering (EXSCEL) clinical trial will find out if giving people with type 2 diabetes a drug called Exenatide alongside their usual diabetes care regime can reduce their risk of heart disease.
EXSCEL is a phase IIIb/IV multinational trial, being conducted in around 30 countries across Australasia, Asia, Europe, North America and Latin America.
Coordinated by DTU and Duke Clinical Research Institute (DCRI), and sponsored by Amylin Pharmaceuticals LLC, (a wholly owned subsidiary of AstraZeneca) the trial began in June 2010.
14,000 people with type 2 diabetes aged 18 years or older whose HbA1c is ≥6.5% and ≤10% will be recruited to the trial. Each participant will receive an injection of study medication (Exenatide/Placebo) once a week. The recruitment period is expected to be around 5 years and an additional 2 - 3 years follow up may be required (total duration of up to approximately 7.5 years)
We expect that results of this pragmatic trial (which aims to measure how beneficial a treatment would be in real clinical practice) will be available in 2018.